RecruitingNCT06887192

ML-007C-MA for Psychosis Associated With Alzheimer's Disease

The registry lists this study as recruiting. Study locations are listed in the United States, in France, in Canada, ... Confirm recruitment at each site. It is testing ML-007C-MA for Psychosis Associated With Alzheimer's Disease.

SchizophreniaDrugFrom 55 Years to 90 Years

The study in practice

Understand this study

Who could participate?

Listed age limits: 55 years to 90 years.

Listed locations: Phoenix, United States · Scottsdale, United States and 53 more locationsSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 15, 2025

Recruitment status: Recruiting
Enrollment listed in the registry: 300
Sponsor: MapLight Therapeutics
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, France, Canada, ...
Age range: From 55 Years to 90 Years
Official registry ID: NCT06887192
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Want help reviewing this study?

Study ID: NCT06887192. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Recruiting

Phoenix, United States · Scottsdale, United States · Tucson, United States

53 more locations

Anaheim, United States
Long Beach, United States
Murrieta, United States
Orange, United States
San Diego, United States
Denver, United States
Boca Raton, United States
Deerfield Beach, United States
Doral, United States
Homestead, United States
Miami, United States
Miami Gardens, United States
Naples, United States
Orlando, United States
Tampa, United States
West Palm Beach, United States
Augusta, United States
Snellville, United States
Alexandria, United States
Las Vegas, United States
West Long Branch, United States
New York, United States
Dayton, United States
Independence, United States
Tigard, United States
Port Royal, United States
Austin, United States
McKinney, United States
Sugarland, United States
Bellevue, United States
Caba, Argentina
Córdoba, Argentina
Pernik, Bulgaria
Sofia, Bulgaria
Brampton, Canada
London, Canada
Toronto, Canada
Lévis, Canada
Antofagasta, Chile
Santiago, Chile
Choceň, Czechia
Prague, Czechia
Toulouse, France
Pécs, Hungary
Roma, Italy
Plewiska, Poland
Torres Vedras, Portugal
Bucharest, Romania
Kragujevac, Serbia
Vranov nad Topľou, Slovakia
Daegu, South Korea
Incheon, South Korea
Czechia

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is MapLight Therapeutics.

Does this study involve medication?

Yes. The study involves medication, including ML-007C-MA and Placebo.

Who can participate?

Listed age limits: 55 years to 90 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me